Drugs / Xeruborbactam

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07104162 Sep 2025 → Jul 2026 overdue bacterial infectious disease Qpex Biopharma, Inc. Recruiting No outcome recorded
Phase 1 NCT07083817 Aug 2025 Qpex Biopharma, Inc. Completed No outcome recorded
Phase 1 NCT06157242 Nov 2024 → Mar 2025 bacterial infectious disease Qpex Biopharma, Inc. Completed No outcome recorded
Phase 1 NCT06547554 Sep 2024 → Oct 2025 bacterial infectious disease Qpex Biopharma, Inc. Completed No outcome recorded
Phase 1 NCT06079775 Jan 2024 → Jan 2025 bacterial infectious disease Qpex Biopharma, Inc. Completed No outcome recorded
Phase 1 NCT05072444 Nov 2021 bacterial infectious disease Qpex Biopharma, Inc. Completed No outcome recorded
Phase 1 NCT04380207 Nov 2020 → Aug 2022 bacterial infectious disease Qpex Biopharma, Inc. Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Xeruborbactam ClinicalTrials.gov intervention name — accepted as the source's own label NCT06157242
4

NCT06547554

NCT07083817

NCT07104162

NCT06079775

Known as QPX-7728 DISODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL4633785
Known as QPX7728 “investigational broad-spectrum beta-lactamase inhibitor (BLI), xeruborbactam (QPX7728)” NCT07104162
2

NCT05072444

NCT04380207

Known as QPX7728 sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL4633785
Known as Xeruborbactam Oral Prodrug “A Phase 1, Open-Label, Drug-drug Interaction, and Randomized, Double-blind, Controlled, Multiple-dose Pharmacokinetics and Safety Study of Xeruborbactam Oral Prodrug (QPX7831)...” NCT06079775
Known as XERUBORBACTAM SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL4633785
Action Inhibit “QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor” NCT04380207
Modality Small molecule “a new boron-based beta-lactamase inhibitor” NCT06079775
Route Intravenous Intravenous (IV) QPX7728” NCT04380207